106 related articles for article (PubMed ID: 33636961)
1. Interassay Comparison of the Tumor Markers CA125, CA15.3, and CA27.29.
Winston-McPherson GN; Merrill AE; Lo SY; Hoofnagle AN; Greene DN
J Appl Lab Med; 2017 Jul; 2(1):17-24. PubMed ID: 33636961
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Gion M; Mione R; Leon AE; Dittadi R
Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
[TBL] [Abstract][Full Text] [Related]
3. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
[TBL] [Abstract][Full Text] [Related]
4. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.
van Rossum HH; Holdenrieder S; Ballieux BEPB; Badrick TC; Yun YM; Zhang C; Patel D; Thelen M; Song J; Wojtalewicz N; Unsworth N; Vesper HW; Cui W; Ramanathan LV; Sturgeon C; Meng QH
Clin Chem; 2024 Apr; 70(4):669-679. PubMed ID: 38385453
[TBL] [Abstract][Full Text] [Related]
5. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
Yedema C; Massuger L; Hilgers J; Servaas J; Poels L; Thomas C; Kenemans P
Int J Cancer Suppl; 1988; 3():61-7. PubMed ID: 3209301
[TBL] [Abstract][Full Text] [Related]
6. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Comparability of Wantai Wan200+ Instrument with Routine Laboratory Assays for 21 Different Analytes.
Talli I; Padoan A; Cosma C; Furlan G; Zaninotto M; Marchioro L; Galozzi P; Basso D; Plebani M
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673517
[No Abstract] [Full Text] [Related]
11. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.
Dehaghani AS; Ghiam AF; Hosseini M; Mansouri S; Ghaderi A
Pathol Oncol Res; 2007; 13(4):360-4. PubMed ID: 18158573
[TBL] [Abstract][Full Text] [Related]
12. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
13. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
[TBL] [Abstract][Full Text] [Related]
14. Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.
Fang C; Cao Y; Liu X; Zeng XT; Li Y
Oncotarget; 2017 Sep; 8(38):63963-63970. PubMed ID: 28969044
[TBL] [Abstract][Full Text] [Related]
15. Microchip fluorescence-enhanced immunoaasay for simultaneous quantification of multiple tumor markers.
Shi M; Zhao S; Huang Y; Liu YM; Ye F
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(26):2840-4. PubMed ID: 21873123
[TBL] [Abstract][Full Text] [Related]
16. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
17. Influence of four different PTH methods on the classification of chronic kidney disease patients according to the new KDIGO guideline.
Ten BE; Van Veen MC; Vervloet MG; Fischer JC; Koopman MG; Van Dam B
Clin Lab; 2012; 58(7-8):719-24. PubMed ID: 22997972
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Bayer Advia Centaur immunoassay results obtained on samples collected in four different Becton Dickinson Vacutainer tubes.
Morovat A; James TS; Cox SD; Norris SG; Rees MC; Gales MA; Taylor RP
Ann Clin Biochem; 2006 Nov; 43(Pt 6):481-7. PubMed ID: 17132279
[TBL] [Abstract][Full Text] [Related]
19. Comparison of four automated serum vitamin B12 assays.
İspir E; Serdar MA; Ozgurtas T; Gulbahar O; Akın KO; Yesildal F; Kurt İ
Clin Chem Lab Med; 2015 Jul; 53(8):1205-13. PubMed ID: 25720078
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
